These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2112201)

  • 1. Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.
    Meyskens FL; Kopecky K; Samson M; Hersh E; Macdonald J; Jaffe H; Crowley J; Coltman C
    J Natl Cancer Inst; 1990 Jun; 82(12):1071. PubMed ID: 2112201
    [No Abstract]   [Full Text] [Related]  

  • 2. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon.
    Landthaler M; Braun-Falco O
    J Am Acad Dermatol; 1989 Apr; 20(4):687-8. PubMed ID: 2497156
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Long HJ; Frytak S; Sherwin SA; Chang MN
    Cancer Treat Rep; 1987 Sep; 71(9):843-4. PubMed ID: 3113730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon therapy in malignant melanoma].
    Kokoschka EM; Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant therapy with recombinant interferon alfa-2a in metastasized malignant melanoma].
    Elsässer-Beile U; Garbe C; Stadler R; Drews H; Schöpf E
    Hautarzt; 1989 May; 40(5):266-70. PubMed ID: 2737901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
    Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
    Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent laryngeal metastasis of a malignant melanoma: surgical therapy with the first application of mitomycin C.
    Echternach M; Arndt S; Mattern D; Maier W; Richter B
    J Otolaryngol Head Neck Surg; 2009 Feb; 38(1):E19-22. PubMed ID: 19344599
    [No Abstract]   [Full Text] [Related]  

  • 9. The Sunbelt Melanoma Trial.
    McMasters KM
    Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant therapy of melanoma patients with gamma interferon].
    Landthaler M; Braun-Falco O
    Hautarzt; 1987 Aug; 38(8):479-80. PubMed ID: 3115915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
    Saiag P
    Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interferon in the treatment of malignant melanoma. Results of clinical studies].
    Elsässer-Beile U; Drews H
    Fortschr Med; 1987 Jun; 105(21):401-3, 42. PubMed ID: 3305266
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. First comment].
    Windeler J; Lange S; Trampisch HJ
    Hautarzt; 1994 Mar; 45(3):189-90; author reply 193-4. PubMed ID: 8175351
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment].
    Gefeller O; Kleeberg U; Kölmel KF
    Hautarzt; 1994 Mar; 45(3):191-2; author reply 193-4. PubMed ID: 8175352
    [No Abstract]   [Full Text] [Related]  

  • 16. [After excision of primary stage I cutaneous melanoma, is an initial evaluation necessary?].
    Richard-Lallemand MA
    Ann Dermatol Venereol; 1995; 122(5):349-59. PubMed ID: 8572478
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of Stage I cutaneous melanoma.
    Berdeaux DH; Moon TE; Meyskens FL
    Ariz Med; 1983 Nov; 40(11):768-72. PubMed ID: 6661064
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.